Pfizer Inc. (NYSE:PFE) Shares Sold by Bremer Bank National Association

Bremer Bank National Association trimmed its position in Pfizer Inc. (NYSE:PFE) by 14.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 13,467 shares of the biopharmaceutical company’s stock after selling 2,212 shares during the period. Bremer Bank National Association’s holdings in Pfizer were worth $357,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Thrivent Financial for Lutherans grew its position in Pfizer by 2.8% during the 2nd quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock worth $20,684,000 after purchasing an additional 20,140 shares during the period. Sompo Asset Management Co. Ltd. grew its position in Pfizer by 15.1% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 22,470 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 2,950 shares during the period. Schwerin Boyle Capital Management Inc. grew its position in Pfizer by 8.2% during the 2nd quarter. Schwerin Boyle Capital Management Inc. now owns 775,125 shares of the biopharmaceutical company’s stock worth $21,688,000 after purchasing an additional 58,850 shares during the period. Kowal Investment Group LLC grew its position in Pfizer by 10.3% during the 2nd quarter. Kowal Investment Group LLC now owns 18,834 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 1,757 shares during the period. Finally, ProShare Advisors LLC grew its position in Pfizer by 7.3% during the 2nd quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock worth $23,661,000 after purchasing an additional 57,825 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Trading Down 0.7 %

PFE opened at $26.30 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $26.08 and its two-hundred day simple moving average is $27.99. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company posted ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.